AV-101 vs BI 1569912
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
AV-101
Developed by VistaGen Therapeutics
NCT02484456 · Phase 2 · completed
Nineteen participants were randomized to receive AV-101 and placebo in a double-blind crossover design. The primary clinical depression endpoint was not statistically significant at the reported time points; for example, the day-0 comparison was 20.22 with AV-101 versus 20.56 with placebo (p=0.68), and the day-13 comparison was 21.52 versus 19.69 (p=0.26).
Reported efficacy
Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 1); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 2); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 3); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 7); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 13): Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) (missed)
Result source: NCT02484456
BI 1569912
Developed by Boehringer Ingelheim
NCT06280235 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.
Reported efficacy
Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) (missed)
Result source: NCT06558344
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AV-101 | BI 1569912 |
|---|---|---|
| MADRS, change (acute) | 30.4 vs 28.6+1.8 vs placeboNCT024844565 other results
| -12.3 vs -12−0.3 vs placeboNCT0628023510 other results
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | 34.8% vs 33.8%+1 vs placeboNCT062802355 other results
|
| MADRS remission | —Not reported | 21.2% vs 19.7%+1.5 vs placeboNCT062802352 other results
|
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- AV-101
- 30.4 vs 28.6+1.8 vs placeboNCT02484456
5 other results
- 29.9 vs 30.8 NCT02484456
- 29.5 vs 29.8 NCT02484456
- 28.8 vs 28.8 NCT02484456
- 29.7 vs 27.1 NCT02484456
- 29.3 vs 29.5 NCT02484456
- BI 1569912
- -12.3 vs -12−0.3 vs placeboNCT06280235
10 other results
- -10 vs -10.3 NCT06558344
- -19.9 vs -19.3 NCT04937829
- -11.9 vs -12 NCT06280235
- -10.6 vs -10.3 NCT06558344
- -16.8 vs -19.3 NCT04937829
- -7.8 vs -12 NCT06280235
- -13.6 vs -10.3 NCT06558344
- -5.7 vs -6.4 NCT06280235
- -5.9 vs -6.4 NCT06280235
- -5.2 vs -6.4 NCT06280235
CGI-S, change (acute)
- AV-101
- —Not reported
- BI 1569912
- —Not reported
MADRS response
- AV-101
- —Not reported
- BI 1569912
- 34.8% vs 33.8%+1 vs placeboNCT06280235
5 other results
- 15.5% vs 11.3% NCT06280235
- 31.4% vs 33.8% NCT06280235
- 11.1% vs 11.3% NCT06280235
- 20.6% vs 33.8% NCT06280235
- 11.1% vs 11.3% NCT06280235
MADRS remission
- AV-101
- —Not reported
- BI 1569912
- 21.2% vs 19.7%+1.5 vs placeboNCT06280235
2 other results
- 25.7% vs 19.7% NCT06280235
- 8.8% vs 19.7% NCT06280235
Relapse (% of patients)
- AV-101
- —Not reported
- BI 1569912
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. AV-101: 2 of 4 rows · BI 1569912: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | AV-101 | BI 1569912 |
|---|---|---|
| Dropout rate | —1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result—1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 | 9.6%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results7.3%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 12.5%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 9.6%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 14.6%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 17.1%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5%20 mg NCT04937829 · Phase 1 15%5 mg NCT04937829 · Phase 1 |
| Discontinued due to AEs | —1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result—1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 | 2.4%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results4.9%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 2.7%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 4.9%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —20 mg NCT04937829 · Phase 1 —5 mg NCT04937829 · Phase 1 |
| Serious AEs | 5.3%1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result5.3%1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 | 1.2%20 mga NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results2.4%10 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%20 mg NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 2.4%10 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%5 mg NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%20 mg NCT04937829 · Phase 1 0%5 mg NCT04937829 · Phase 1 |
| Most frequent reported AEs | 1,080 mg for 1 Week headache 26.3% (placebo 15.8%) insomnia 15.8% (placebo 10.5%) musculoskeletal pain 15.8% (placebo 15.8%) NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result1,440 mg for 1 Week abdominal discomfort 5.3% (placebo 10.5%) asthenia 5.3% (placebo 0%) cold sweat 5.3% (placebo 0%) NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 | 20 mga dizziness 8.4% (placebo 2.5%) headache 8.4% (placebo 6.3%) nasopharyngitis 4.8% (placebo 3.8%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 7 more results10 mg headache 4.9% (placebo 6.3%) upper respiratory tract infection 2.4% (placebo 6.3%) dizziness 0% (placebo 2.5%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5 mg headache 7.5% (placebo 6.3%) nasopharyngitis 7.5% (placebo 3.8%) upper respiratory tract infection 5% (placebo 6.3%) NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20 mg headache 12.3% (placebo 7.9%) nasopharyngitis 8.2% (placebo 3.9%) diarrhoea 2.7% (placebo 1.3%) NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2 10 mg headache 9.8% (placebo 7.9%) diarrhoea 4.9% (placebo 1.3%) nasopharyngitis 4.9% (placebo 3.9%) NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 5 mg headache 14.3% (placebo 7.9%) diarrhoea 5.7% (placebo 1.3%) upper respiratory tract infection 5.7% (placebo 1.3%) NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20 mg decreased appetite 5% (placebo 5.3%) blood pressure increased 0% (placebo 0%) constipation 0% (placebo 0%) NCT04937829 · Phase 1 5 mg blood pressure increased 10% (placebo 0%) constipation 10% (placebo 0%) headache 5% (placebo 5.3%) NCT04937829 · Phase 1 |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
AV-101
show 5 more results
show 5 more results
show 5 more results
BI 1569912
show 5 more results
show 2 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AV-101's landscape · BI 1569912's landscape